Gresele Paolo, Falcinelli Emanuela, Bury Loredana, Pecci Alessandro, Alessi Marie-Christine, Borhany Munira, Heller Paula G, Santoro Cristina, Cid Ana Rosa, Orsini Sara, Fontana Pierre, De Candia Erica, Podda Gianmarco, Kannan Meganathan, Jurk Kerstin, Castaman Giancarlo, Falaise Céline, Guglielmini Giuseppe, Noris Patrizia
Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
J Thromb Haemost. 2021 May;19(5):1364-1371. doi: 10.1111/jth.15263.
The ISTH Bleeding Assessment Tool (ISTH-BAT) has been validated for clinical screening of suspected von Willebrand disease (VWD) and for bleeding prediction. Recently it has been validated for subjects with inherited platelet disorders (IPD) (BAT-VAL study).
To determine whether the ISTH-BAT bleeding score (BS) predicts subsequent bleeding events requiring treatment in IPD patients.
Patients with IPD, type 1 VWD (VWD-1) and age- and sex-matched healthy controls enrolled in the BAT-VAL study were prospectively followed-up for 2 years and bleeding episodes requiring treatment were recorded.
Of the 1098 subjects initially enrolled, 955 were followed-up and 124 suffered hemorrhages during follow-up, 60% of whom had inherited platelet function disorders (IPFD). Total number of events was significantly higher in IPFD (n = 235) than VWD-1 (n = 52) or inherited thrombocytopenia (IT; n = 20). Events requiring transfusions were 66% in IPFD, 5.7% in VWD-1, and 3% in IT. Baseline BS was significantly higher in IPFD patients with a bleeding event at follow-up than in those without (p < .01) and the percentage of subjects suffering a bleeding event increased proportionally to baseline BS quartile. A significant association between the BS and the chance of suffering severe bleeding was found in the overall, IPFD, and VWD-1 populations. Similar results were obtained for the pediatric population.
Inherited platelet function disorder patients with high BS at enrollment are more likely to suffer from bleeding events requiring treatment at follow-up. Moreover, the higher the baseline BS quartile the greater the incidence of subsequent events, suggesting that independently from diagnosis a high BS is associated with a greater risk of subsequent hemorrhage.
国际血栓与止血学会出血评估工具(ISTH-BAT)已被验证可用于疑似血管性血友病(VWD)的临床筛查和出血预测。最近,它已在遗传性血小板疾病(IPD)患者中得到验证(BAT-VAL研究)。
确定ISTH-BAT出血评分(BS)是否能预测IPD患者随后需要治疗的出血事件。
对参加BAT-VAL研究的IPD患者、1型VWD(VWD-1)患者以及年龄和性别匹配的健康对照进行了为期2年的前瞻性随访,并记录了需要治疗的出血事件。
在最初纳入的1098名受试者中,955名接受了随访,124名在随访期间发生了出血,其中60%患有遗传性血小板功能障碍(IPFD)。IPFD患者的事件总数(n = 235)显著高于VWD-1患者(n = 52)或遗传性血小板减少症(IT;n = 20)患者。IPFD患者中需要输血的事件占66%,VWD-1患者中占5.7%,IT患者中占3%。随访时有出血事件的IPFD患者的基线BS显著高于无出血事件的患者(p <.01),发生出血事件的受试者百分比与基线BS四分位数成比例增加。在总体人群、IPFD人群和VWD-1人群中,BS与发生严重出血的可能性之间存在显著关联。儿科人群也获得了类似结果。
入组时BS较高的遗传性血小板功能障碍患者在随访期间更有可能发生需要治疗的出血事件。此外,基线BS四分位数越高,随后事件的发生率越高,这表明独立于诊断之外,高BS与随后出血的风险更大相关。